Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P10321
UPID:
HLAC_HUMAN
Alternative names:
HLA-Cw; Human leukocyte antigen C
Alternative UPACC:
P10321; O02863; O02864; O02865; O02866; O02958; O19505; O19652; O19676; O62879; O62882; O62883; O62888; O78060; O78061; O78062; O78063; O78067; O78068; O78069; O78072; O78083; O78090; O78091; O78149; O78165; O78166; O78178; O78202; O78203; O78211; O78214; P04222; P30499; P30500; P30501; P30502; P30503; P30504; P30505; P30506; P30507; P30508; P30509; P30510; P79498; Q07000; Q29631; Q29641; Q29643; Q29652; Q29743; Q29768; Q29862; Q29864; Q29865; Q29867; Q29921; Q29959; Q29960; Q29963; Q29986; Q29989; Q29990; Q29991; Q29992; Q29993; Q30192; Q31605; Q31627; Q860R1; Q860R2; Q95463; Q95603; Q95604; Q99528; Q9BD28; Q9GIK4; Q9GIK8; Q9GJ33; Q9MY30; Q9MY31; Q9MY35; Q9MY49; Q9MY74; Q9MYI3; Q9TNN7; Q9TNZ8; Q9TPS4; Q9TPV8; Q9TPX2; Q9TQB4; Q9TQJ5; Q9TQP9; Q9UM32; Q9UM33; Q9UM42; Q9UQS9
Background:
HLA class I histocompatibility antigen, C alpha chain (HLA-C), plays a pivotal role in immune response, reproduction, and antiviral defense. It presents a restricted repertoire of self and viral peptides, acting as a ligand for killer immunoglobulin receptors on NK cells and guiding T cell immune response to eliminate infected cells.
Therapeutic significance:
HLA-C's involvement in diseases like Psoriasis 1, through allele-specific interactions, highlights its potential as a target for therapeutic strategies. Understanding HLA-C's role could open doors to novel treatments for autoimmune and viral diseases.